Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 2, 2009, Pages 758-766

  Leopoldo, Marcello ^a   Lacivita, Enza ^a   De Giorgio, Paola ^a   Contino, Marialessandra ^a   Berardi, Francesco ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Arylpiperazine; D3 receptors; Lipophilicity; Positron emission tomography; Structure affinity relationships

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N [4 [4 [2 (2 FLUOROETHOXY)PHENYL]PIPERAZIN 1 YL]BUTYL] 2,1,3 BENZOXADIAZOLE 5 CARBOXAMIDE; N [4 [4 [2 (2 FLUOROETHOXY)PHENYL]PIPERAZIN 1 YL]BUTYL] 4 (1H IMIDAZOL 1 YL)BENZAMIDE; N [4 [4 [3 (2 FLUOROETHOXY)PHENYL]PIPERAZIN 1 YL]BUTYL] 4 (1H IMIDAZOL 1 YL)BENZAMIDE; N [4 [4 [3 FLUORO 5 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (1H IMIDAZOL 1 YL)BENZAMIDE; QUINPIROLE; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; ISOMER; ISOTOPE LABELING; LIGAND BINDING; LIPOPHILICITY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOASSAY; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

AMIDES; DRUG DESIGN; HUMANS; LIGANDS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D3;

EID: 58549088678     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.11.044     Document Type: Article

References (42)

1. Lee C.M., and Farde L. Trends Pharmacol. Sci. 27 (2006) 310
2. Guilloteau D., and Chalon S. Curr. Pharm. Des. 11 (2005) 3237
3. de Paulis T. Curr. Pharm. Des. 9 (2003) 673
4. Kumar J.S., and Mann J.J. Drug Discovery Today 12 (2007) 748
5. Yu M. Curr. Top. Med. Chem. 7 (2007) 1800
6. Lever J.R. Curr. Pharm. Des. 13 (2007) 33
7. Yasuno F., Brown A.K., Zoghbi S.S., Krushinski J.H., Chernet E., Tauscher J., Schaus J.M., Phebus L.A., Chesterfield A.K., Felder C.C., Gladding R.L., Hong J., Halldin C., Pike V.W., and Innis R.B. Neuropsychopharmacology 33 (2008) 259
8. Sibley D.R., Monsma Jr. F.J., and Shen Y. Int. Rev. Neurobiol. 35 (1993) 391
9. Sealfon S.C., and Olanow C.W. Trends Neurosci. 23 (2000) S34
10. Richtand N.M., Woods S.C., Berger S.P., and Strakowski S.M. Neurosci. Biobehav. Rev. 25 (2001) 427
11. Joyce J.N., and Millan M.J. Drug Discovery Today 10 (2005) 917
12. Joyce J.N., Ryoo H.L., Beach T.B., Caviness J.N., Stacy M., Gurevich E.V., Reiser M., and Adler C.H. Brain Res. 955 (2002) 138
13. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., and Sokoloff P. Nat. Med. 9 (2003) 762
14. Heidbreder C.A., Gardner E.L., Xi Z.-X., Thanos P.K., Mugnaini M., Hagan J.J., and Ashby C.R. Brain Res. Rev. 49 (2005) 77
15. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwarz J.C. Nature 347 (1990) 72
16. Luedtke R.R., and Mach R.H. Curr. Pharm. Des. 9 (2003) 643
17. Boeckler F., and Gmeiner P. Biochim. Biophys. Acta 1768 (2007) 871
18. Huang, Y.; Martinez, D.; Simpson, N.; Guo, N.; Montoya, J.; Laruelle, M. Abstracts Soc. Neurosci. 2000, abstr. # 809.9, p 2154.
19. Turolla E.A., Matarrese M., Belloli S., Moresco R.M., Simonelli P., Todde S., Fazio F., Magni F., Galli Kienle M., Leopoldo M., Berardi F., Colabufo N.A., Lacivita E., and Perrone R. J. Med. Chem. 48 (2005) 7018
20. Kuhnast B., Valette H., Besret L., Demphel S., Coulon C., Ottaviani M., Guillermier M., Bottlaender M., and Dollé F. Nucl. Med. Biol. 33 (2006) 785
21. Gao M., Mock B.H., Hutchins G.D., and Zheng Q.-H. Bioorg. Med. Chem. 13 (2005) 6233
22. Hocke C., Prante O., Löber S., Hübner H., Gmeiner P., and Kuwert T. Bioorg. Med. Chem. Lett. 15 (2008) 4819
23. Sóvágó J., Farde L., Halldin C., Langer O., Laszlovszky I., Kiss B., and Gulyás B. Neurochem. Int. 45 (2004) 609
24. de Vries E.F., Kortekaas R., van Waarde A., Dijkstra D., Elsinga P.H., and Vaalburg W. J. Nucl. Med. 46 (2005) 1384
25. Laruelle M., Slifstein M., and Huang Y. Mol. Imaging Biol. 5 (2003) 363
26. Waterhouse R.N. Mol. Imaging Biol. 5 (2003) 376
27. Leopoldo M., Lacivita E., De Giorgio P., Colabufo N.A., Niso M., Berardi F., and Perrone R. J. Med. Chem. 49 (2006) 358
28. Shealy Y.F., Krauth C.A., Struck R.F., and Montgomery J.A. J. Med. Chem. 26 (1983) 1168
29. Gyertyán I., Kiss B., Gál K., Laszlovszky I., Horváth A., Gémesi L.I., Sághy K., Pásztor G., Zájer M., Kapás M., Csongor E.A., Domány G., Tihanyi K., and Szombathelyi Z. J. Pharmacol. Exp. Ther. 320 (2007) 1268
30. Haupt A., Grandel R., Braje W., Geneste H., Drescher K., Starck D., and Teschendorf H.-J. Chem. Abstr. 142 (2004) 38277
31. Unger L., Haupt A., Beyerbach A., Drescher K., Braje W., Darbyshire J., Turner S.C., and Backfisch G. Chem. Abstr. 145 (2006) 46089
32. Hocke C., Prante O., Salama I., Hübner H., Löber S., Kuwert T., and Gmeiner P. Chem. Med. Chem. 3 (2008) 788
33. Perrone R., Berardi F., Leopoldo M., Tortorella V., Lograno M.D., Daniele E., and Govoni S. Farmaco 50 (1995) 505
34. Campiani G., Butini S., Fattorusso C., Trotta F., Franceschini S., De Angelis M., and Nielsen K. Chem. Abstr. 145 (2006) 14551
35. Comer J.E., and Tam K.Y. In: Testa B., van de Waterbeemd H., Folkers G., and Guy R.H. (Eds). Pharmacokinetic Optimization in Drug Research (2001), Wiley-VCH, Zürich 275-304
36. Avdeef A. Quant. Struct.-Act. Relat. 11 (1992) 510
37. Avdeef A. J. Pharm. Sci. 82 (1993) 183
38. Avdeef A. In: Pilska V., Testa B., and van de Waterbeemd H. (Eds). Lipophilicity in Drug Action and Toxicology (1996), VCH Publishers, Weinheim 109-139
39. Avdeef A., Box K.J., Comer J.E., Gilges M., Hadley M., Hibbert C., Patterson W., and Tam K.Y. J. Pharm. Biomed. Anal. 20 (1999) 631
40. Scarselli M., Novi F., Schallmach E., Lin R., Baragli A., Colzi A., Griffon N., Corsini G.U., Sokoloff P., Levenson R., Vogel Z., and Maggio R. J. Biol. Chem. 276 (2001) 30308
41. GraphPad Prism Software (version for Windows), GraphPad Software, Inc., San Diego, CA, USA.
42. Cheng Y.C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099